Tenax Net Income From Continuing Ops from 2010 to 2024

TENX Stock  USD 6.04  0.32  5.59%   
Tenax Therapeutics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -7.4 M in 2024. During the period from 2010 to 2024, Tenax Therapeutics Net Loss regression line of annual values had significance of  0.25 and arithmetic mean of (10,832,071). View All Fundamentals
 
Net Loss  
First Reported
2001-06-30
Previous Quarter
-3.8 M
Current Value
-3.6 M
Quarterly Volatility
6.5 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tenax Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tenax Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.2 K, Other Operating Expenses of 8.4 M or Research Development of 3.6 M, as well as many indicators such as Price To Sales Ratio of 141.3 K, Dividend Yield of 3.31 or PTB Ratio of 0.71. Tenax financial statements analysis is a perfect complement when working with Tenax Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tenax Therapeutics Correlation against competitors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Latest Tenax Therapeutics' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Tenax Therapeutics over the last few years. It is Tenax Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tenax Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Tenax Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(10,832,071)
Coefficient Of Variation(138.10)
Mean Deviation9,490,577
Median(9,415,800)
Standard Deviation14,958,776
Sample Variance223.8T
Range59.6M
R-Value(0.31)
Mean Square Error217.1T
R-Squared0.1
Significance0.25
Slope(1,052,990)
Total Sum of Squares3132.7T

Tenax Net Income From Continuing Ops History

2024-7.4 M
2023-7 M
2022-11 M
2021-32.5 M
2020-9.9 M
2019-8.4 M
2018-6.8 M

About Tenax Therapeutics Financial Statements

Tenax Therapeutics investors use historical fundamental indicators, such as Tenax Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tenax Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-7 M-7.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.